IL160715A0 - Pharmaceutical compositions containing an a1 adenosine receptor antagonist - Google Patents

Pharmaceutical compositions containing an a1 adenosine receptor antagonist

Info

Publication number
IL160715A0
IL160715A0 IL16071502A IL16071502A IL160715A0 IL 160715 A0 IL160715 A0 IL 160715A0 IL 16071502 A IL16071502 A IL 16071502A IL 16071502 A IL16071502 A IL 16071502A IL 160715 A0 IL160715 A0 IL 160715A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
compositions containing
receptor antagonist
adenosine receptor
adenosine
Prior art date
Application number
IL16071502A
Other languages
English (en)
Original Assignee
Biogen Idec Inc
Musc Found For Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Musc Found For Res Dev filed Critical Biogen Idec Inc
Publication of IL160715A0 publication Critical patent/IL160715A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16071502A 2001-09-06 2002-09-06 Pharmaceutical compositions containing an a1 adenosine receptor antagonist IL160715A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31790801P 2001-09-06 2001-09-06
PCT/US2002/028580 WO2003022284A1 (en) 2001-09-06 2002-09-06 Methods of treating pulmonary disease

Publications (1)

Publication Number Publication Date
IL160715A0 true IL160715A0 (en) 2004-08-31

Family

ID=23235775

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16071502A IL160715A0 (en) 2001-09-06 2002-09-06 Pharmaceutical compositions containing an a1 adenosine receptor antagonist

Country Status (20)

Country Link
US (1) US20040259889A1 (pl)
EP (1) EP1429775A4 (pl)
JP (2) JP4388373B2 (pl)
KR (1) KR100979738B1 (pl)
CN (1) CN1564688A (pl)
AU (1) AU2002341618B2 (pl)
BR (1) BR0212329A (pl)
CA (1) CA2459533A1 (pl)
EA (1) EA014684B1 (pl)
GE (1) GEP20074132B (pl)
HU (1) HUP0401805A3 (pl)
IL (1) IL160715A0 (pl)
IS (1) IS7163A (pl)
MX (1) MXPA04002135A (pl)
NZ (1) NZ532083A (pl)
PL (1) PL368935A1 (pl)
UA (1) UA80258C2 (pl)
WO (1) WO2003022284A1 (pl)
YU (1) YU20104A (pl)
ZA (1) ZA200401765B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS107404A (sr) * 2002-06-12 2007-02-05 Biogen Idec Ma Inc., Metod lečenja ishemične povrede izazvane poremećajem perfuzije upotrebom antagonista adenozinskog receptora
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
AU2004233852A1 (en) * 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
US7247639B2 (en) * 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
CA2648281A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine a1 receptor antagonists and anticonvulsants
EP2035009A1 (en) * 2006-06-16 2009-03-18 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
ATE486874T1 (de) 2006-06-23 2010-11-15 Incyte Corp Purinonderivate als hm74a-agonisten
AR061625A1 (es) 2006-06-23 2008-09-10 Incyte Corp Derivados de purinona como agonistas de hm74a
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2009055021A1 (en) * 2007-10-26 2009-04-30 New York University School Of Medicine Methods and compositions for treating hepatic diseases
US20090228097A1 (en) * 2008-03-07 2009-09-10 Abbott Cardiovascular Systems Inc. A1 Adenosine Receptor Antagonist-Coated Implantable Medical Device
WO2009152458A1 (en) * 2008-06-13 2009-12-17 Biogen Idec Ma Inc. Liquid formulation suitable for infusion comprising an adenosine receptor antagonist for treating heart failure and renal insufficiency.
BR112012032766A2 (pt) * 2010-06-30 2019-09-24 Gilead Sciences Inc uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonar
AU2014244482B2 (en) * 2013-03-14 2018-01-25 Bristol-Myers Squibb Company Bicyclo [2.2.2] acid GPR120 modulators
IL275817B2 (en) 2018-01-04 2024-04-01 Impetis Biosciences Ltd Tricyclic compounds, compositions and medicinal applications thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208240A (en) * 1991-03-12 1993-05-04 Merrell Dow Pharmaceuticals Inc. 8-substituted purines as selective adenosine receptor agents
TW252044B (pl) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
ATE226583T1 (de) * 1996-06-07 2002-11-15 Hoechst Ag Verwendung von theophyllinderivaten zur behandlung und propylaxe von schockzuständen, neue xanthinverbindungen und verfahren zu deren herstellung
GB9723553D0 (en) * 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
ZA9810766B (en) * 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity
CA2312867A1 (en) * 1998-01-09 1999-07-15 The Trustees Of The University Of Pennsylvania Compositions and methods for use in ischemia-reperfusion and endotoxin-related tissue injury
EP0970696A1 (en) * 1998-05-05 2000-01-12 Kyowa Hakko Kogyo Co., Ltd. Combination of loop diuretics with adenosine A1-receptor antagonists
CA2390496A1 (en) * 1999-11-12 2001-05-17 Biogen, Inc. Polycycloalkylpurines as adenosine receptor antagonists
WO2001039777A1 (en) * 1999-12-02 2001-06-07 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof

Also Published As

Publication number Publication date
WO2003022284A1 (en) 2003-03-20
ZA200401765B (en) 2005-04-05
EA200400399A1 (ru) 2004-08-26
JP2009209156A (ja) 2009-09-17
NZ532083A (en) 2005-10-28
US20040259889A1 (en) 2004-12-23
HUP0401805A3 (en) 2007-05-02
CA2459533A1 (en) 2003-03-20
KR100979738B1 (ko) 2010-09-09
YU20104A (sh) 2006-08-17
MXPA04002135A (es) 2005-03-07
GEP20074132B (en) 2007-06-25
IS7163A (is) 2004-02-26
BR0212329A (pt) 2004-09-21
CN1564688A (zh) 2005-01-12
AU2002341618B2 (en) 2008-06-26
PL368935A1 (pl) 2005-04-04
UA80258C2 (en) 2007-09-10
EP1429775A1 (en) 2004-06-23
JP2005501915A (ja) 2005-01-20
EA014684B1 (ru) 2010-12-30
KR20040040457A (ko) 2004-05-12
JP4388373B2 (ja) 2009-12-24
EP1429775A4 (en) 2007-04-11
HUP0401805A2 (hu) 2004-12-28

Similar Documents

Publication Publication Date Title
HUP0203870A3 (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
IL187604A0 (en) Pharmaceutical compositions containing an interleukin-6 antagonist
HUP0401437A3 (en) Adenosine a3 receptor agonists
HUP0401925A3 (en) A2b adenosine receptor antagonists
IL176122A0 (en) Pharmaceutical compositions containing an interleukin-6 antagonist
IL174909A0 (en) Pharmaceutical compositions containing an interleukin-6 antagonist
IL159725A0 (en) Pharmaceutical compositions containing benzimidazole derivatives
IL161716A0 (en) ADENOSINE A2a RECEPTOR ANTAGONISTS
EP1551402A4 (en) PHARMACEUTICAL COMPOSITIONS NOT INDUCING ABUSE
IL155810A0 (en) Nmda receptor agonist pharmaceutical compositions
IL161572A0 (en) Adenosine a2a receptor antagonists
EG24194A (en) 5ht-a-partial agonist pharmaceutical compositions
IL169575A0 (en) Calcium-sensing receptor antagonist compounds and pharmaceutical compositions containing the same
HUP0303533A3 (en) Adenosine a1 agonist adenosine derivatives
PL370799A1 (pl) Pochodne aminotetraliny jako antagoniści receptorów muskarynowych
HUP0201300A3 (en) Il-8 receptor antagonist imidazoidinylidene-2-imino derivatives and pharmaceutical compositions containing them
GB0104752D0 (en) Pharmaceutical compositions
AU2002359524A8 (en) P2x7 receptor antagonists
IL160438A0 (en) Pharmaceutical compositions containing an angiotensin ii receptor antagonist
EP1636230A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
AU2002328569A1 (en) Medicinal compositions containing angiotensin II receptor antagonist
HUP0402108A3 (en) Macrolides containing pharmaceutical compositions
HUP0300181A3 (en) Vitronectin receptor antagonist bicyclic compounds, their preparation and pharmaceutical compositions containing same
PL368613A1 (pl) Kompozycja farmaceutyczna zawierająca antagonistęLTB4
IL131864A0 (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist